Interviews

Alvaro Alencar, MD, associate professor of clinical medicine, chief medical officer, University of Miami Sylvester Comprehensive Cancer Center, examines disparities in lymphoma outcomes using retrospective data from cooperative groups over 15 years.

Payers want to make sure patients are getting biopsies done so they can get on the right therapies, said Bhuvana Sagar, MD, Oncology Consultants.

The top 5 most-viewed content from this year's American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease (CVD) Prevention included interviews with Robert Kushner, MD, MS, and Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC, as well as coverage on multiple areas of cardiovascular medicine.

The SEQUOIA study's 5-year follow-up confirms zanubrutinib's safety profile and low cardiovascular events in treatment-naive chronic lymphocytic leukemia, according to Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center.

Meghan Gutierrez, CEO of the Lymphoma Research Foundation, highlights key topics and takeaways that attendees can expect from this year's meeting.

Top coverage from the European Respiratory Society (ERS) Congress 2024 spanned various topics, including artificial intelligence–powered robots transforming respiratory care and late-breaking findings on an epilepsy drug showing promise for treating obstructive sleep apnea.

National Recovery Month is recognized each year in September, and for 2024, we marked the month with a special podcast and exclusive video series with our Strategic Alliance Partner, UPMC Health Plan.

On this episode of Managed Care Cast, we speak with CVS Health's vice president and chief medical officer for women's health and genomics about advancements and challenges in women's health, focusing on care access, technology, and maternal outcomes.

Divya Gupta, MD, assistant professor at the Northwestern University Feinberg School of Medicine, emphasized the transformative role of biomarker-driven therapies in advancing non–small cell lung cancer (NSCLC) treatment and highlighted the critical importance of multidisciplinary collaboration.

Gene therapies can be life-changing for people, but the high cost plus the burden of treatment remain barriers to access and utilization, explained Kevin Niehoff, PharmD, BCMAS, of IPD Analytics.

The US can learn from what other countries are doing well to implement the best programs to improve patient access to care, especially for those who have the worst outcomes, explained Nadine J. Barrett, PhD, MA, MS, FACCC, of Wake Forest University and the Association of Cancer Care Centers.

Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed recent advancements in multiple myeloma treatment, including the potential of cell therapies and bispecific antibodies.

Sandra Cuellar, PharmD, from the University of Illinois Chicago, highlights the critical role of real-world data in shaping reimbursement models for oncology therapies and emphasizes the growing importance of patient-centered care through shared decision-making, precision medicine, and patient-reported outcomes.

Matias Sanchez, MD, assistant professor in the Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago, emphasizes the importance of patient education and caregiver involvement in managing complex therapies and advises oncologists to confidently integrate advanced treatments.

Palliative care is quality care, and providers and health systems need to do a better job at ensuring there is equity in palliative care, said Nadine J. Barrett, PhD, MA, MS, FACCC, of Wake Forest University and the Association of Cancer Care Centers.

Divya Gupta, MD, assistant professor at Feinberg School of Medicine at Northwestern University, discussed the potential of using circulating tumor DNA and minimal residual disease (MRD) assays for personalized treatment in non–small cell lung cancer (NSCLC), while emphasizing the unmet need for effective second-line therapies for patients without driver mutations.

Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing bispecifics to the community.

On this episode of Managed Care Cast, we speak with the author of a study published in the November 2024 issue of The American Journal of Managed Care® to explore the link between utilization management and physician burnout.

Attendees of the centennial American Heart Association (AHA) conference commend the meeting's ability to bring together diverse, interdisciplinary perspectives from across the globe.

On November 20, the FDA approved bimekizumab (Bimzelx; UCB Pharma) for use in patients with moderate to severe hidradenitis suppurativa.

In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.

The Wellness Way facility was designed to improve access to comprehensive outpatient care and address social determinants of health for a diverse patient population.

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses the latest advancements in HR+/HER2– breast cancer research, as well as the increasing role of genomic profiling in tailoring treatment plans.

In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat non–small cell lung cancer (NSCLC).

The implementation of a risk evaluation mitigation strategy (REMS) program to monitor patients on mavacamten further supports its real-world use, according to Milind Desai, MD, Cleveland Clinic.

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

New discoveries in atherosclerosis pathways have shed light on the active mechanisms in other diseases such as chronic kidney disease (CKD) and HIV, paving the way for furture therapeutics.

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.